{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:23:31Z","timestamp":1726759411984},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T08:12:20Z","timestamp":1305015140000},"page":"187-201","source":"Crossref","is-referenced-by-count":12,"title":["Treatment strategies in advanced stage follicular lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Marinus H.J.","family":"van Oers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"5 Suppl. 5","key":"10.1016\/j.beha.2011.03.003_bib2","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.003_bib3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.beha.2011.03.003_bib4","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.003_bib6","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood.V110.11.3428.3428","article-title":"Survival in follicular lymphoma: the Stanford experience, 1960\u20132003","volume":"110","author":"Tan","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2011.03.003_bib7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","article-title":"No initial therapy for stage III and IV non-Hodgkin\u2019s lymphomas of favorable histologic types","volume":"90","author":"Portlock","year":"1979","journal-title":"Ann Intern Med"},{"issue":"292","key":"10.1016\/j.beha.2011.03.003_bib9","first-page":"651","article-title":"The natural history of low grade non-Hodgkin\u2019s lymphoma and the impact of a no initial treatment policy on survival","volume":"80","author":"O\u2019Brien","year":"1991","journal-title":"Q J Med"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2 Suppl. 2","key":"10.1016\/j.beha.2011.03.003_bib11","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"issue":"9383","key":"10.1016\/j.beha.2011.03.003_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.beha.2011.03.003_bib13","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.003_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.003_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib16","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib18","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00a0\u00d7\u00a04 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2011.03.003_bib19","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.003_bib20","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"18 Suppl.","key":"10.1016\/j.beha.2011.03.003_bib21","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/jco.2007.25.18_suppl.8008","article-title":"Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy","volume":"25","author":"Federico","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.beha.2011.03.003_bib22","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3324\/haematol.11502","article-title":"Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study","volume":"92","author":"Federico","year":"2007","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.beha.2011.03.003_bib23","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2011.03.003_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.beha.2011.03.003_bib27","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib28","first-page":"1605","article-title":"The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma","volume":"91","author":"Alvaro","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"de Jong","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.003_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2013a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"de Jong","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib32","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/blood-2006-11-058040","article-title":"Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival","volume":"109","author":"Cerhan","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2011.03.003_bib34","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.003_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.V104.11.589.589","article-title":"Fc{gamma} receptor polymorphisms do not Influence progression free survival (PFS) of follicular NHL patients treated with Chop followed by rituximab (SWOG 9800)","volume":"104","author":"Maloney","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2011.03.003_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","article-title":"Immunoglobulin G Fc receptor FcgammaRIIIa 158 V\/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"28","author":"Weng","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib37","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib38","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib39","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.003_bib42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 Years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2011.03.003_bib43","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.003_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.beha.2011.03.003_bib45","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib46","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.003_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added {alpha}IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2011.03.003_bib48","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2011.03.003_bib49","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.003_bib51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.beha.2011.03.003_bib52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival \u2013 A study from the groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.beha.2011.03.003_bib53","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.003_bib54","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib55","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.003_bib56","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.003_bib57","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.003_bib58","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib59","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.10894","article-title":"Rituximab maintenance therapy: a step forward in follicular lymphoma","volume":"92","author":"van Oers","year":"2007","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.beha.2011.03.003_bib60","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib61","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","article-title":"Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment","volume":"105","author":"Glas","year":"2005","journal-title":"Blood"},{"issue":"4 Suppl. 4","key":"10.1016\/j.beha.2011.03.003_bib63","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2013similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"issue":"21","key":"10.1016\/j.beha.2011.03.003_bib64","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.beha.2011.03.003_bib65","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib66","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.V114.22.1669.1669","article-title":"A phase I\/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B -Cell (DLBCL) and follicular grade 3 lymphoma","volume":"114","author":"Nowakowski","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib67","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.V114.22.1679.1679","article-title":"R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma (NHL)","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib68","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood.V114.22.1714.1714","article-title":"A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin\u2019s lymphoma","volume":"114","author":"Fowler","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.003_bib69","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.beha.2011.03.003_bib70","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib71","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib72","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib73","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di","year":"2010","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.beha.2011.03.003_bib74","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib76","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood.V114.22.1711.1711","article-title":"Phase 1\/2a study of ABT-263 in relapsed or refractory lymphoid malignancies","volume":"114","author":"Wilson","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib77","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood.V114.22.883.883","article-title":"An ongoing phase 1\/2a study of ABT-263; pharmacokinetics (PK), safety and anti-tumor activity in patients (pts) with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"114","author":"Roberts","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2011.03.003_bib78","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.003_bib79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2011.03.003_bib82","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.V114.22.935.935","article-title":"Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma","volume":"114","author":"Hagenbeek","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib84","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.03.003_bib85","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V114.22.1704.1704","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ non-Hodgkin lymphoma (NHL)","volume":"114","author":"Salles","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib86","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib87","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2011.03.003_bib88","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.003_bib89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin\u2019s lymphoma. A randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2011.03.003_bib90","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0142(19870715)60:2<156::AID-CNCR2820600205>3.0.CO;2-K","article-title":"The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin\u2019s lymphoma","volume":"60","author":"Ezdinli","year":"1987","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib91","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","article-title":"Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin\u2019s lymphoma: results from a prospective, multicenter trial with double randomization","volume":"16","author":"Arranz","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"10.1016\/j.beha.2011.03.003_bib92","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10428199609052435","article-title":"Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival","volume":"20","author":"Aviles","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/bjoc.2001.1822","article-title":"A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma","volume":"85","author":"Rohatiner","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2011.03.003_bib94","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin\u2019s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib95","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin\u2019s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809","volume":"18","author":"Fisher","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib97","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib98","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2011.03.003_bib99","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.003_bib100","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.003_bib101","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"15 Suppl.","key":"10.1016\/j.beha.2011.03.003_bib102","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2010.28.15_suppl.8004","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib103","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.003_bib104","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.beha.2011.03.003_bib105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clon.2005.11.015","article-title":"Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab","volume":"18","author":"Fogarty","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"10.1016\/j.beha.2011.03.003_bib106","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"issue":"(6) Suppl. 2","key":"10.1016\/j.beha.2011.03.003_bib107","article-title":"First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/0","volume":"94","author":"Hitz","year":"2009","journal-title":"Haematologica"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T16:54:23Z","timestamp":1712422463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000302"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}